AVITA Medical, Inc.
RCEL · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.12 | -0.19 | 0.25 | -1.29 |
| FCF Yield | -7.71% | -4.93% | -2.90% | -3.96% |
| EV / EBITDA | -21.19 | -20.08 | -37.17 | -20.98 |
| Quality | ||||
| ROIC | -29.54% | -25.39% | -16.50% | -21.56% |
| Gross Margin | 81.17% | 84.70% | 87.61% | 83.68% |
| Cash Conversion Ratio | 1.03 | 0.74 | 0.70 | 0.45 |
| Growth | ||||
| Revenue 3-Year CAGR | 22.39% | 24.17% | 23.13% | 23.46% |
| Free Cash Flow Growth | -1.99% | -8.52% | 11.92% | 28.53% |
| Safety | ||||
| Net Debt / EBITDA | -3.99 | -2.41 | -3.24 | -1.85 |
| Interest Coverage | -8.90 | -9.59 | -7.67 | -10.16 |
| Efficiency | ||||
| Inventory Turnover | 0.46 | 0.34 | 0.31 | 0.51 |
| Cash Conversion Cycle | 63.92 | 50.09 | 96.98 | 118.81 |